Rilzabrutinib
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 67 publications
Bruton protein-tyrosine kinase (BTK) FDA-approved small molecule inhibitors used for the management of neoplastic and inflammatory disorders.
Journal: Pharmacological research
Published: March 31, 2026
Immune thrombocytopenia: contemporary pathophysiology, treatment gaps, and the role of novel mechanisms in patient-centered care.
Journal: The American journal of managed care
Published: January 28, 2026
Properties of FDA-approved small molecule protein kinase inhibitors: A 2026 update.
Journal: Pharmacological research
Published: January 20, 2026
Rilzabrutinib and the evolving landscape of oral therapies for uncontrolled asthma.
Journal: The Lancet. Respiratory medicine
Published: December 29, 2025
Management of autoimmune hemolytic anemia.
Journal: Hematology. American Society of Hematology. Education Program
Published: December 05, 2025
Synthetic oxetanes in drug discovery: where are we in 2025?
Journal: Expert opinion on drug discovery
Published: December 01, 2025
Rilzabrutinib in immune thrombocytopenia: a targeted, patient-centered alternative to conventional therapies.
Journal: Annals of medicine and surgery (2012)
Published: November 20, 2025
Translational immunothrombosis in autoimmune Heparin-Induced thrombocytopenia: targeting the FcγRIIa-Syk-BTK and complement pathways.
Journal: Clinical and experimental medicine
Published: November 05, 2025
Rilzabrutinib and Bruton tyrosine kinase inhibition for the treatment of persistent or chronic immune thrombocytopenia.
Journal: Expert opinion on pharmacotherapy
Published: October 13, 2025
Rilzabrutinib.
Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Published: October 08, 2025
Bruton's tyrosine kinase inhibition in ITP: Wayrilz (rilzabrutinib) as a disease-modifying strategy.
Bruton's tyrosine kinase inhibition in ITP: Wayrilz (rilzabrutinib) as a disease-modifying strategy.
Journal: Annals of medicine and surgery (2012)
Published: October 01, 2025
Last Updated: 04/28/2026